GRAIL (company)

HCA Healthcare and Grail Collaborate to Advance Comprehensive Cancer Care With Multi-Cancer Early Detection Screening

Retrieved on: 
Dienstag, Oktober 17, 2023
Research, Other Health, General Health, Oncology, Hospitals, Surgery, Clinical Trials, Science, Biotechnology, Nursing, Practice Management, Health, Other Science, GRAIL, Partnership, Multimedia, Cancer, NYSE, Health care, American Cancer Society, Breast, MD, Clinical professor, HCA, FACEP, Education, SCRI, Colon, Lung, HCA Healthcare, Prostate, Sarah Cannon Research Institute, Patient, Hospital, Medical imaging, GRAIL (company)

HCA Healthcare, Inc. (NYSE: HCA), one of the nation’s leading healthcare providers, Sarah Cannon Cancer Institute, part of HCA Healthcare, and GRAIL, LLC, a healthcare company with a mission of detecting cancer early when it can be cured, today announced a strategic collaboration to advance comprehensive cancer care through early detection.

Key Points: 
  • HCA Healthcare, Inc. (NYSE: HCA), one of the nation’s leading healthcare providers, Sarah Cannon Cancer Institute, part of HCA Healthcare, and GRAIL, LLC, a healthcare company with a mission of detecting cancer early when it can be cured, today announced a strategic collaboration to advance comprehensive cancer care through early detection.
  • Starting today, GRAIL’s Galleri® multi-cancer early detection (MCED) test will be available to patients who meet screening criteria at select HCA Healthcare physician practices.
  • View the full release here: https://www.businesswire.com/news/home/20231017721204/en/
    More than 600,000 people die from cancer each year in the U.S., according to the American Cancer Society.
  • “Sarah Cannon has been working with GRAIL for several years to advance the study of early cancer detection testing,” said Dax Kurbegov, MD, vice president and physician-in-chief of Clinical Programs at Sarah Cannon Cancer Institute.

Accarent Health to Offer GRAIL’s Galleri®, a Multi-Cancer Early Detection Test to its Network and Members

Retrieved on: 
Montag, Oktober 2, 2023
Health, Cancer, Breast, Prostate, Lung, Colon, GRAIL, Patient, Diagnosis, American Cancer Society, Ecosystem, Medical imaging, MD, GRAIL (company)

Baltimore, MD, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Accarent Health announced today the availability of Galleri®, a multi-cancer early detection (MCED) screening test to its network of patients, self-insured employers, plan administrators, brokers, and other ecosystem partners.

Key Points: 
  • Baltimore, MD, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Accarent Health announced today the availability of Galleri®, a multi-cancer early detection (MCED) screening test to its network of patients, self-insured employers, plan administrators, brokers, and other ecosystem partners.
  • "Accarent Health is thrilled to offer the Galleri test by GRAIL, a pioneer in early cancer detection technology.
  • The Galleri test can detect a shared cancer signal across more than 50 types of cancer through a routine blood draw.
  • In fact, about 71% of cancer deaths are from cancers that lack recommended early detection screening.

Point32Health and GRAIL Expand Pilot Access to Galleri® Multi-Cancer Early Detection Blood Test

Retrieved on: 
Donnerstag, September 28, 2023
Oncology, Medical Supplies, Health, Medical Devices, Other Health, Pharmaceutical, Biotechnology, Insurance, History of health care reform in the United States, Harvard Pilgrim Health Care, Cancer, Breast, Massachusetts General Hospital, Research, Prostate, MSHS, Trial of the century, Colon, Harvard Medical School, Lung, Tufts Health Plan, PCP, GRAIL, Patient, Risk, Mass, Mass General Brigham, Diagnosis, American Cancer Society, MPH, Health insurance, Medical imaging, MD, GRAIL (company), Medicine

“We are excited to expand our pilot to include Mass General Brigham by offering members this early detection screening test that could potentially save countless lives.”

Key Points: 
  • “We are excited to expand our pilot to include Mass General Brigham by offering members this early detection screening test that could potentially save countless lives.”
    Point32Health is the first commercial health plan in the U.S. to work with GRAIL to offer its Galleri screening test in addition to recommended cancer screenings.
  • The initial pilot program enabled access to Galleri at no cost for eligible Point32Health employees and Harvard Pilgrim Health Care members who purchase their insurance on the Maine health insurance marketplace.
  • As part of this pilot, Mass General Cancer Center’s Early Detection and Diagnostics Clinic will assess eligible participants for cancer risk and have the test available for those members at no cost.
  • In fact, about 71 percent of cancer deaths are from cancers that lack recommended early detection screening.

John Hancock Convenes Global Leaders in Longevity Innovation in Boston, Joined by Mayor Wu

Retrieved on: 
Dienstag, September 12, 2023
Tufts University, New England Hospital for Women and Children, Nutrition, RAND, World Economic Forum, Policy, University, Sleep, Ageing, Cancer, Dimock, Longevity, Symposium (Plato), Research, MIT, Life expectancy, Science, Organization, Athlete, University of Massachusetts Boston, GRAIL, Friedman School of Nutrition Science and Policy, City, Physician, Symposium, John Hancock, Diagnosis, Health, MPH, Boston Public Health Commission, Vitality, Wellness, Pharmaceutical industry, Veterinary medicine, Nursing, Manulife, MD, GRAIL (company)

Hosts its First-Ever Symposium Reaffirming Commitment to Helping People Live Longer, Healthier, Better Lives

Key Points: 
  • Hosts its First-Ever Symposium Reaffirming Commitment to Helping People Live Longer, Healthier, Better Lives
    BOSTON, Sept. 12, 2023 /PRNewswire/ - Today, John Hancock , a unit of Toronto-based Manulife, is hosting its first-ever Longevity Symposium in Boston, joined by Mayor Michelle Wu.
  • It's time we work together to win the battle on deteriorating health," said Brooks Tingle, President and CEO of John Hancock.
  • "We're proud to host this event in Boston — an epicenter for longevity innovation across science, health and wellness, technology, finance, policy.
  • Since 2015, John Hancock has offered customers access to its industry-leading John Hancock Vitality Program, which motivates and rewards customers for the small, everyday things they do to stay healthy or improve their health.

Whitman-Walker Institute, Cancer Support Community and GRAIL Collaborate On Research Aimed at Advancing Health Equity in Cancer Screening and Care Through Multi-Cancer Early Detection

Retrieved on: 
Mittwoch, August 23, 2023
Oncology, Public Policy, Government, Health, Healthcare Reform, Medical Devices, Clinical Trials, Biotechnology, Tissue, Partnership, Whitman-Walker Health, Education, Principal investigator, CSC, Policy, Health equity, Cancer, Breast, Research, Cancer Support Community, Prostate, Lung, Colon, Implementation, GRAIL, Incidence, Estate (law), MD, Risk, INCLUDE, Diagnosis, Mortality, American Cancer Society, Navigation, MPH, Pharmaceutical industry, Nursing, Medical imaging, LGBTQ, Doctor of Philosophy, GRAIL (company)

The Implementation and Navigation of Cancer Liquid biopsy to Understand Diverse Patient Experiences (INCLUDE) study will evaluate established community outreach strategies intended to build awareness and increase early cancer screening.

Key Points: 
  • The Implementation and Navigation of Cancer Liquid biopsy to Understand Diverse Patient Experiences (INCLUDE) study will evaluate established community outreach strategies intended to build awareness and increase early cancer screening.
  • As part of the collaboration, eligible individuals will be invited by Whitman-Walker to participate in this real-world study being undertaken in collaboration with Cancer Support Community.
  • For individuals who receive a Galleri cancer signal detected test result, Cancer Support Community will offer professionally-led support and navigation services, from diagnosis to treatment and survivorship.
  • Recent studies have also shown an elevated rate of cancer diagnosis for members of the LGBTQ community.

Mercy Names Dana Haynie of Oklahoma to Lead Cancer Services

Retrieved on: 
Montag, August 21, 2023
Heart, Mayo Clinic, Life, National Research Corporation, Marketing, Elective surgery, Pharmacy, GRAIL (company), Accountable care organization, Health, Cancer, Cure, Woman, Research, Multimedia, CTCA, Cancer Treatment Centers of America, Hospital, Neuroscience, Patient, Physician, Haynie, Medicine, Diagnosis, GI, Breast cancer, Nursing, Mercy

ST. LOUIS and OKLAHOMA CITY, Aug. 21, 2023 /PRNewswire/ -- Mercy has named a new leader to grow and transform cancer services for patients in Arkansas, Kansas, Missouri and Oklahoma.

Key Points: 
  • ST. LOUIS and OKLAHOMA CITY, Aug. 21, 2023 /PRNewswire/ -- Mercy has named a new leader to grow and transform cancer services for patients in Arkansas, Kansas, Missouri and Oklahoma.
  • Dana Haynie will serve as Mercy's service line president for cancer care.
  • Haynie was previously president and chief executive officer at Cancer Treatment Centers of America (CTCA) in Tulsa, Oklahoma, part of a national network of hospitals that specialized in the treatment of patients fighting complex or advanced-stage cancer.
  • Haynie will collaborate with Mercy physicians and leaders across Arkansas, Missouri, Kansas and Oklahoma to align, further develop, and grow these services.

US Wellness to Offer GRAIL's Galleri®, a Multi-Cancer Early Detection Test, To Its Network of Employers

Retrieved on: 
Dienstag, August 1, 2023
If Memory Serves Us Well, Cancer, Breast, Prostate, Lung, Colon, Organization, GRAIL, Diagnosis, American Cancer Society, Health, Medical imaging, GRAIL (company)

"US Wellness' mission is to provide innovative solutions that inspire people to live healthier, be stronger, and achieve more.

Key Points: 
  • "US Wellness' mission is to provide innovative solutions that inspire people to live healthier, be stronger, and achieve more.
  • "The Galleri multi-cancer early detection test gives us a powerful tool to address cancer risk by identifying cancer early.
  • We believe that Galleri has the potential to help employers reduce cancer claims and address traditional health disparities in cancer detection and screening."
  • In fact, about 71% of cancer deaths are a result of cancers that lack early detection screening.

GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting

Retrieved on: 
Samstag, Juni 3, 2023
Oncology, Medical Supplies, Health, Health Technology, General Health, Research, Science, Lymphoma, Pancreatic cancer, CSD, Ovary, CSO, Pancreas, Cancer, Esophagus, Head, Breast, Multimedia, Risk, Prostate, Neck, Uterus, Lung, II, ASCO, Incidence, Sarcoma, DO, Lymphoid leukemia, American Society of Clinical Oncology, Adventist Health, MD, Patient, Surveillance, Annual general meeting, Kidney, Systematic, SEER, Diagnosis, Society, Medical imaging, Epidemiology, GRAIL, GRAIL (company)

The findings were presented during a poster discussion session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • The findings were presented during a poster discussion session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • As part of the clinical surveillance program, GRAIL follows CSD results by contacting ordering providers 3 months or more after the Galleri test result to collect cancer outcomes.
  • One of the patients for whom Galleri detected a lethal cancer early is Roger Royse, who took the test at age 62.
  • We continue to see an average cancer signal detection rate of 1%, which as expected increases with age.

GRAIL to Present New Multi-Cancer Early Detection Data at the 2023 ASCO Annual Meeting

Retrieved on: 
Montag, Mai 22, 2023
Oncology, Health, Technology, Health Technology, Software, Biotechnology, Abstract (summary), CSO, ESMO, Annual Meetings of the International Monetary Fund and the World Bank Group, Cancer, Ageing, MSHS, European Society for Medical Oncology, ASCO, Congress, Initial, American Society of Clinical Oncology, MD, Patient, Risk, Annual general meeting, Methylation, Society, Medical imaging, GRAIL, GRAIL (company), Mercy

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, will present new data evaluating the use and potential of its methylation-based multi-cancer early detection (MCED) platform at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2-6.

Key Points: 
  • GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, will present new data evaluating the use and potential of its methylation-based multi-cancer early detection (MCED) platform at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2-6.
  • An evaluation of Galleri implementation using a centralized model within Mercy’s multi-state health system will also be presented.
  • Abstracts will be available on the 2023 ASCO Annual Meeting website .
  • Updated analyses will be presented at the Annual Meeting.

FirstHealth of the Carolinas to Offer GRAIL’s Galleri®, a Multi-Cancer Early Detection Blood Test

Retrieved on: 
Dienstag, April 18, 2023
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Hospitals, Clinical Trials, Other Health, Partnership, Cancer, Breast, Prostate, Trial of the century, Colon, Lung, GRAIL, American Joint Committee on Cancer, MD, Patient, Risk, Ageing, American Cancer Society, Pharmaceutical industry, Medical imaging, GRAIL (company)

FirstHealth will be the first health system in North Carolina to offer the Galleri MCED test to those at an elevated risk of cancer, including those aged 50 or older, as part of its comprehensive cancer screening and care.

Key Points: 
  • FirstHealth will be the first health system in North Carolina to offer the Galleri MCED test to those at an elevated risk of cancer, including those aged 50 or older, as part of its comprehensive cancer screening and care.
  • Additional primary care clinics will offer the test in the coming months.
  • In fact, about 71% of cancer deaths are from cancers that lack recommended early detection screening.
  • To learn more about the GalleriⓇ MCED test offered through FirstHealth Concierge Medicine, call (800) 213-3284.